Rodrigo Mata, MD
Internal Medicine · Kenosha, WINPI 1033148176
Payments from drug & device makers
Across 185 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$791
- Novo Nordisk$599
- Lilly USA, LLC$517
- Astellas Pharma US Inc$383
- Boehringer Ingelheim$333
- Nestle Healthcare Nutrition Inc.$228
- plus $2K from 24 others
What the payments were for
- Travel & lodging$30%
- Food & beverage$4,28094%
- Education$2876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $791 |
| Novo Nordisk | 20 | $599 |
| Lilly USA, LLC | 21 | $517 |
| Astellas Pharma US Inc | 11 | $383 |
| Boehringer Ingelheim | 15 | $333 |
| Nestle Healthcare Nutrition Inc. | 6 | $228 |
| AbbVie(2 entities) | 12 | $223 |
| Abbott | 9 | $183 |
| Recor Medical Inc | 5 | $181 |
| Pfizer | 7 | $136 |
| Sunovion Pharmaceuticals Inc. | 6 | $129 |
| Novartis | 5 | $83 |
| Exact Sciences | 4 | $81 |
| IBSA Pharma Inc. | 5 | $73 |
| Aimmune Therapeutics, Inc. | 3 | $72 |
| GSK | 5 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Merck | 4 | $63 |
| Johnson & Johnson | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Nevro Corp. | 2 | $33 |
| Bayer | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,570 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 16 | $111,672 |
| OzempicSemaglutide | 39 | $74,777 |
| EliquisApixaban | 73 | $71,686 |
| TrulicityDulaglutide | 43 | $63,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $61,781 |
| RybelsusSemaglutide | 23 | $50,531 |
| JardianceEmpagliflozin | 34 | $49,745 |
| MounjaroTirzepatide | 20 | $39,992 |
| JanuviaSitagliptin Phosphate | 32 | $39,894 |
| FarxigaDapagliflozin Propanediol | 25 | $29,260 |
| XareltoRivaroxaban | 39 | $28,580 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $24,416 |
| VraylarCariprazine Hcl | 11 | $14,441 |
| LinzessLinaclotide | 13 | $13,944 |
| MyrbetriqMirabegron | 13 | $12,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $599 | $125,30862 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $517 | $103,28263 claims |
| PfizerEliquis, Paxlovid | $136 | $75,96687 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $333 | $74,16163 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $72 | $74,02365 claims |
| MerckJanuvia | $63 | $39,89432 claims |
| AstraZenecaFarxiga | $791 | $29,26025 claims |
| Johnson & JohnsonXarelto | $49 | $28,58039 claims |
| AbbVieVraylar, Linzess | $223 | $28,38524 claims |
| Astellas Pharma US IncMyrbetriq | $383 | $12,66713 claims |
| Sanofi-aventis U.S. LLCLantus | $37 | $2,97824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Kenosha
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.